Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.

Plain-language summary

This study examines the molecular features and treatment outcomes of patients with aggressive B-cell lymphoma, a fast-growing lymph cancer. Patients aged 18 and older who were histologically diagnosed between 2000 and 2019 and treated with anthracycline-based chemotherapy (such as R-CHOP) were included. This was a study without a clinical phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Andrés José Maria Ferreri

Intervention

Treatments: anthracycline-based combinations followed or not by involved-field radiotherapy

Start date

7/12/2022

Estimated completion

7/12/2023

Countries

Italy

Related genes

Locations

• Milan, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

* Histologically-confirmed diagnosis of LBCL (i.e., DLBCL, HGBCL, unclassifiable B-cell lymphoma with features intermediate between DLBCL and BL), or aggressive B-cell lymphomas with blastoid morphology (excluding blastoid variant of mantle cell lymphoma and lymphoblastic lymphoma)
* Histopathological diagnosis performed between 2000 and 2019.
* HIV sero-negativity
* Age ≥18
* Treatment with R-CHOP or other intensified polychemotherapy regimen
* Availability of adequate histopathological samples at diagnosis for FISH analysis
* Availability of clinical records and outcomes data

Exclusion criteria

• Histologic diagnosis other than DLBCL or unclassifiable B-cell lymphoma with features intermediate between DLBCL and BL